Table 2.
Current clinical trials related to hypoxia signaling and organ protection
| Disease | Study condition | Intervention | Outcome measures | https://ClinicalTrials.gov Identifier (status) |
|---|---|---|---|---|
| Heart | Postoperative myocardial ischemia in pancreatic surgery | Remote ischemic preconditioning | Postoperative myocardial injury and inflammatory response | NCT03460938 (recruiting) |
| Myocardial injury after percutaneous coronary intervention (PCI) | Remote ischemic preconditioning | Troponin | NCT02581618 (completed) | |
| Myocardial injury after non-cardiac surgery | Remote ischemic preconditioning | Troponin | NCT02427867 (recruiting) | |
| Perioperative myocardial ischemia in elective operation of abdominal aortic aneurysm | Remote ischemic preconditioning | CKMB and Troponin T | NCT01523262 (unknown) | |
| Myocardial injury after PCI | Remote ischemic preconditioning | Myocardial injury and cardiac events | NCT00970827 (completed) | |
| Myocardial damage in patients undergoing coronary artery bypass graft (CABG) surgery | Epoetin-α | Erk1/2, STAT5, Akt and caspase-3, CKMB, Troponin T, NT-proBNP | NCT00524901 (completed) | |
| Minimally invasive mitral valve (MIMV) repair or replacement | Volatile conditioning (sevoflurane) used during induction (preconditioning) | NCT02551328 (recruiting) | ||
| Adult patient undergoing open heart surgery | Sevoflurane versus ischemic and Sevoflurane preconditioning | Postoperative inotropic score | NCT02715869 (completed) | |
| Chronic heart failure, NYHA class II–IV | Neladenoson bialanate (BAY1067197, ADORA1 agonist) | LVEF (%), NT-proBNP, Troponin T | NCT02992288 (completed) | |
| Lung | Lung injury during elective lung lobectomy | Remote ischemic preconditioning | Oxidative lung injury | NCT02734654 (completed) |
| Lung injury during CABG surgery | Remote Ischemic preconditioning and postconditioning | Pulmonary parameters and plasma IL-6, IL-8, IL-10, TNF-α levels | NCT01144585 (completed) | |
| Lung transplantation | Regadenoson (ADORA2A agonist) | Activation of iNKT cells, pulmonary graft dysfunction, inflammatory cytokines | NCT03072589 (recruiting) | |
| Liver | Non-alcoholic steatohepatitis (NASH) | CF102 (ADORA3 agonist) | ALT, AST, HDL cholesterol | NCT02927314 (recruiting) |
| Kidney | Contrast-induced acute kidney injury | Remote ischemic preconditioning | Creatinine, vascular and renal biomarkers | NCT03236441 (recruiting) |
| Stage III–IV chronic kidney disease undergoing planned coronary angiography | Remote ischemic preconditioning | Proinflammatory gene expression and anti-inflammatory gene expression in leukocytes, local release of adenosine and NO | NCT02167152 (completed) | |
| Acute kidney injury in patients undergoing valvular heart surgery | Human recombinant erythropoietin | Incidence of acute kidney injury | NCT01758861 (completed) | |
| Non-dialysis dependent chronic kidney disease | Vadadustat (PHD inhibitor) | Hemoglobin (Hb) | NCT02648347 (recruiting) | |
| Chronic kidney disease patients initiating dialysis | Daprodustat (PHD inhibitor) | Hemoglobin (Hb) | NCT03029208 (recruiting) | |
| Non-dialysis dependent chronic kidney disease | Roxadustat (PHD inhibitor) | Hemoglobin (Hb) | NCT02021318 (active, not recruiting) |